Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease

• Study stage: Closed
• Sponsor: Lille University
• Funder: European Commission Horizon 2020 Grant
• Therapeutic area: Neurological
• Type of study: CTIMP

Aim: To demonstrate for the first time in a large phase II, randomised, placebo-controlled trial that conservative iron chelation, with the prototype drug Deferiprone, will slow down the progression of symptoms in Parkinson's disease patients and will not be associated with a clinically negative benefit / risk ratio.

Primary outcome:

The change in the total MDS-UPDRS score between baseline and 36 weeks (i.e. the end of the placebo-controlled phase for analysis of both disease modifying and symptomatic effects).

• Population: Adult
• Phase: IIb
• Design: RCT
• Setting: Secondary care
• Planned Sample Size: 322